Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Multicenter, Open-Label Study of CTX-712 in Patients With Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

NCT05732103 is registered in ClinicalTrials.gov with Chordia Therapeutics, Inc. as lead sponsor.

NCT NCT05732103
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05732103 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Multicenter, Open-Label Study of CTX-712 in Patients With Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
Lead sponsor
Chordia Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
April 25, 2023
Completion date
February 28, 2029
Enrollment
225 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, myelodysplastic syndromes